首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   23751篇
  免费   1681篇
  国内免费   168篇
耳鼻咽喉   245篇
儿科学   777篇
妇产科学   812篇
基础医学   2856篇
口腔科学   399篇
临床医学   3449篇
内科学   4414篇
皮肤病学   453篇
神经病学   1861篇
特种医学   455篇
外科学   2605篇
综合类   624篇
一般理论   26篇
预防医学   2526篇
眼科学   538篇
药学   1608篇
  1篇
中国医学   167篇
肿瘤学   1784篇
  2023年   145篇
  2022年   243篇
  2021年   602篇
  2020年   423篇
  2019年   579篇
  2018年   608篇
  2017年   461篇
  2016年   544篇
  2015年   648篇
  2014年   859篇
  2013年   1187篇
  2012年   1809篇
  2011年   1944篇
  2010年   1074篇
  2009年   881篇
  2008年   1590篇
  2007年   1671篇
  2006年   1496篇
  2005年   1562篇
  2004年   1473篇
  2003年   1382篇
  2002年   1136篇
  2001年   332篇
  2000年   290篇
  1999年   223篇
  1998年   220篇
  1997年   215篇
  1996年   157篇
  1995年   124篇
  1994年   126篇
  1993年   112篇
  1992年   145篇
  1991年   140篇
  1990年   125篇
  1989年   104篇
  1988年   81篇
  1987年   62篇
  1986年   84篇
  1985年   74篇
  1984年   83篇
  1983年   73篇
  1982年   62篇
  1981年   51篇
  1980年   66篇
  1979年   52篇
  1978年   51篇
  1977年   39篇
  1976年   27篇
  1974年   29篇
  1972年   25篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
3.
4.
5.
There is a large and growing population of long-term cancer survivors. Primary care physicians (PCPs) are playing an increasingly greater role in the care of these patients across the continuum of cancer survivorship. In this role, PCPs are faced with the responsibility of managing a range of medical and psychosocial late effects of cancer treatment. In particular, the sexual side effects of treatment which are common and have significant impact on quality of life for the cancer survivor, often go unaddressed. This is an area of clinical care and research that has received increasing attention, highlighted by the presentation of this special issue on Cancer and Sexual Health. The aims of this review are 3-fold. First, we seek to overview common presentations of sexual dysfunction related to major cancer diagnoses in order to give the PCP a sense of the medical issues that the survivor may present with. Barriers to communication about sexual health issues between patient/PCPs in order are also described in order to emphasize the importance of PCPs initiating this important conversation. Next, we provide strategies and resources to help guide the PCP in the management of sexual dysfunction in cancer survivors. Finally, we discuss case examples of survivorship sexual health issues and highlight the role that a PCP can play in each of these case examples.  相似文献   
6.
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号